Arcutis Biotherapeutics clinical trials we track

Check company identity source

Phase 3 8 trials

Phase 2 6 trials

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Occurrence of treatment emergent AEs (TEAEs). After: Measure: Percentage of Participants With ≥1 Treatment-Emergent Adverse Events (TEAEs) Measure: Percentage of Participants With ≥1 Serious Adverse Events (SAEs).

Actual enrollment increased by 4 participants

Before: 333 participants (actual). After: 337 participants (actual).

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Plasma pharmacokinetic (PK) profile of ARQ-151 cream 0.3% and its major N-oxide metabolite Measure: Incidence of adverse events Measure: Incidence of application site reactions. After: Measure: Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3% Measure: Plasma Concentration of Major N-oxide Metabolite Following Daily Application of Roflumilast Cream 0.3% Measure: Number of Participants With an Adverse Event (AE) Measure: Number of Participants With Application Site Reactions.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 100 participants (planned). After: 101 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Jun 2026. After: 4 Dec 2025.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source